DelphX Announces Grant of Stock Options

Rhea-AI Summary

DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB: DPXCF), a leader in developing new structured products for the fixed income market, has announced the grant of 1,650,000 stock options to eligible participants under its stock option plan. The Board of Directors approved this grant with the following terms:

• Two-year maturity
• Exercise price of $0.25 per common share
• Options are exercisable for common shares of DelphX

This decision aligns with the company's stock option plan and may be seen as a strategy to incentivize and retain key personnel or partners.

Positive

• Grant of 1,650,000 stock options to eligible participants, potentially aligning interests with shareholders
• Two-year maturity on options, encouraging medium-term commitment

Negative

• Potential dilution of existing shareholders if options are exercised

Toronto, Ontario--(Newsfile Corp. - September 23, 2024) - DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB: DPXCF) ("DelphX"), a leader in the development of new classes of structured products for the fixed income market, announces that its Board of Directors has approved the grant of 1,650,000 stock options (the "Options") to eligible participants under its stock option plan (the "Plan"). The Options have a two-year maturity and are exercisable for common shares of DelphX at an exercise price of $0.25 per common share, all in accordance with the Plan.

About DelphX Capital Markets Inc.

DelphX is a technology and financial services company focused on developing and distributing the next generation of structured products. Through its special purpose vehicle Quantem LLC, the Company enables fixed income dealers to offer new private placement securities that provide mitigation of spread and capital charge losses when downgrades occur, while allowing for attractive returns. The new DelphX securities will enable dealers and their qualified institutional investors (QIBs) accounts to competitively structure, sell and make markets in:

• Collateralized put options (CPOs) that provide secured rating downgrade protection for underlying corporate bonds;

• Collateralized reference notes (CRNs) that enable investors to take on a capped rating downgrade exposure of an underlying security in exchange for attractive returns.

All CPOs and CRNs are fully collateralized and held in custody by BNY Mellon. CPOs and CRNs are proprietary products created and owned by DelphX Capital Markets.

For more information about DelphX, please visit www.delphx.com.

George Wentworth, General Manager
DelphX Capital Markets Inc.
george.wentworth@delphx.com

(718) 509-2160

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/224213

FAQ

How many stock options did DelphX Capital Markets (DPXCF) grant on September 23, 2024?

DelphX Capital Markets (DPXCF) granted 1,650,000 stock options on September 23, 2024.

What is the exercise price for the stock options granted by DelphX (DPXCF)?

The exercise price for the stock options granted by DelphX (DPXCF) is $0.25 per common share.

What is the maturity period for the stock options granted by DelphX Capital Markets (DPXCF)?

The stock options granted by DelphX Capital Markets (DPXCF) have a two-year maturity period.

On which stock exchanges is DelphX Capital Markets traded?

DelphX Capital Markets is traded on the TSX Venture Exchange (TSXV: DELX) and the OTCQB market (OTCQB: DPXCF).